1,721,062 research outputs found
Partial vitrectomy for open-globe trauma involving the posterior segment: Avoiding hyaloidectomy and base shaving in early surgery could result in less iatrogenic damage
No full textPartial vitrectomy for open-globe trauma involving the posterior segment: Avoiding hyaloidectomy and base shaving in early surgery could result in less iatrogenic damage
No full text
Intravitreal dexamethasone implant for macular edema following uncomplicated phacoemulsification
No full text
Intravitreal Therapy for Diabetic Macular Edema: An Update
Full text linkDiabetic macular edema (DME) represents a prevalent and disabling eye condition. Despite that DME represents a sight-Threatening condition, it is also among the most accessible to treatment. Many different treatment options including photocoagulation, intravitreal medical treatment (either vascular endothelial growth factor inhibitors or corticosteroids therapies), and surgical removal are currently available. Although laser has been considered as the gold standard for many years, over the past several years vascular endothelial growth factor inhibitors (anti-VEGFs) have become first-line therapy. However, many patients do not adequately respond to them. With the development of sustained-release corticosteroid devices, steroids have gained a presence in the management of the DME. We review and update the role of anti-VEGF and intravitreal sustained-release corticosteroid management of DME. According to the currently available scientific evidence, the choice of one anti-VEGF over another critically depends on the baseline best-corrected visual acuity (BCVA). While aflibercept may be the drug of choice in low baseline BCVA, the three anti-VEGFs (bevacizumab, ranibizumab, and aflibercept) provided similar functional outcomes when the baseline BCVA was higher. DEX implants are a valuable option for treating DME, although they are usually seen as a second choice, particularly in those eyes that have an insufficient response to anti-VEGF. The new evidence suggested that, in eyes that did not adequately respond to anti-VEGF, switching to a DEX implant at the time to 3 monthly anti-VEGF injections provided better functional outcomes
Gentamicin-induced macular infarction in transconjunctival sutureless 25-gauge vitrectomy.
No full textPURPOSE: State Gentamicin antibiotic prophylaxis is contraindicated in 25 gauge Transconjunctival Sutureless Vitrectomy.
METHODS: A 75-year-old diabetic woman was affected by glaucoma and mild diabetic retinopathy in both eyes, and epiretinal membrane in the left eye. A 25-gauge Transconjunctival Sutureless Vitrectomy (TSV) was performed with self-sealing transconjunctival scletomies of the left eye. Post-operation antibiotic prophylaxis was obtained by subconconjunctival injection of Gentamicin sulfate (0.4 mg/ml) adjacent to scletomies.
RESULTS: A month after the operation visual acuity had not recovered. Fluorescein angiography detected occlusion of perifoveal capillaries.
CONCLUSION: Antibiotics, in particular gentamicin, have the potential to cause significant ocular toxicity when they gain access to the inside of the eye, through thinned sclera or sutureless sclerotomies of TSV
- …
